BiotechTube
Helocyte

Helocyte

Foster City, United States· Est.
helocyte.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $55M

Overview

Helocyte is a clinical-stage biotech advancing a pipeline of immunotherapies for cytomegalovirus (CMV) and other infectious diseases. The company's lead candidate, Triplex, is a modified vaccinia Ankara (MVA) vector-based vaccine designed to prevent CMV reactivation in transplant recipients, having progressed into Phase 2 clinical trials. Helocyte operates as a private entity, leveraging strategic partnerships and investor backing to advance its programs in a significant unmet medical market. Its focus on high-risk patient populations, such as hematopoietic stem cell and solid organ transplant patients, positions it in a specialized but critical niche.

Infectious DiseaseTransplantation

Technology Platform

Modified Vaccinia Ankara (MVA) viral vector platform engineered to deliver multiple antigenic targets for eliciting broad cellular and humoral immune responses.

Funding History

2
Total raised:$55M
Series B$35M
Series A$20M

Opportunities

A successful vaccine for CMV in transplant recipients addresses a high-unmet medical need with a clear value proposition, potentially displacing costly and toxic antiviral drugs.
The MVA platform technology is versatile and could be expanded to target other complex infectious diseases.
Positive clinical data could attract strategic partnership or acquisition interest from larger pharma companies with transplantation or vaccine portfolios.

Risk Factors

High clinical development risk as the lead candidate must prove efficacy in a challenging immunocompromised population.
Faces competition from other CMV vaccine modalities (e.g., mRNA) and adoptive T-cell therapies.
As a private, pre-revenue company, it is dependent on raising capital, with funding prospects tightly linked to clinical data readouts.

Competitive Landscape

Helocyte competes in the CMV prophylactic/therapeutic space with several players, including Moderna (mRNA-1647 Phase 3 vaccine for primary prevention) and Merck (prevailed V160 vaccine program discontinued). In the transplant setting, it also competes with antiviral drugs and investigational adoptive T-cell therapies like AlloVir's posoleucel. Its differentiation lies in its multi-antigen MVA vector approach specifically designed for reactivation prevention in seropositive patients.

More companies in Cell & Gene Therapy →More companies in United States →